Join your peers at the only conference dedicated to the leading causes of mortality and morbidity in diabetes, this autumn, in London. Our distinguished faculty unite the fields of pharmacology, nanotechnology and clinical medicine to target atherosclerosis, endothelial inflammation and end-stage renal disease.

SMi's unique program brings together the latest research from those at the forefront of attenuating the complications arising from hyperglycaemia, dyslipidaemia, and angiopathy.

“This conference is an excellent one stop shop to up-skill on current issues in diabetes therapy. I’m happy to chair what will no doubt be a very stimulating session.” – Phil Ambery, Medical Director, GlaxoSmithKline

Key Reasons to Attend:
• Receive clinical updates on novel GLP1 receptor agonists, and SLGT2 and DPP-4 inhibitors
• Utilise biomarkers and imaging for the development of novel therapies for diabetes
• Discuss new therapeutic targets to reduce hypertension, hyperkalaemia and endothelial inflammation in diabetes
• Remain abreast of new EU and FDA guidelines on clinical trials on risk-benefit assessment
• Capitalise on the effects of targeting RAAS, CCN2 and CCN3 inhibitors
• Review clinical results from the DEMAND study

Key Speakers Include:
• James F. List, Vice President and Full Development Lead, Dapagliflozin, Bristol-Myers Squibb
• John Wilding, Professor of Medicine & Honorary Consultant Physician, Head of Department of Obesity and Endocrinology, University of Liverpool Hospital
• Martin Siman, Director, Design and Interpretation Centre of Excellence, AstraZeneca
• Philip Ambery, Director, Clinical Development, GlaxoSmithKline
• Sandra Souza, Team Lead, Molecular Biomarkers, PPDM , Merck Sharp & Dohme

Diabetes: Secondary Complications, Regulation and Innovation, promises to be a unique platform for networking, problem solving and learning from timely case studies. This really is a unique event not to be missed.

Click here to find out more and/or book your place.